H Oettle

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. doi request reprint Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial
    Helmut Oettle
    Medizinische Klinik mit Schwerpunkt Hamatologie, Onkologie und Tumorimmunologie, Charite Universitatsmedizin Berlin, Berlin, Germany
    JAMA 310:1473-81. 2013
  2. pmc Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno Riess
    Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
    BMC Cancer 8:361. 2008
  3. pmc A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Helmut Friess
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    BMC Cancer 6:285. 2006
  4. pmc Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO Study Group, Augustenburger Platz 1, Berlin, Germany
    BMC Cancer 10:86. 2010
  5. ncbi request reprint Recombinant human erythropoietin in the treatment of head and neck tumour anaemia
    H Oettle
    Charite Campus Virchow Klinikum, Medical Faculty of the Humboldt University in Berlin Germany
    Int J Oral Maxillofac Surg 30:148-55. 2001
  6. ncbi request reprint Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial
    Helmut Oettle
    Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    JAMA 297:267-77. 2007
  7. ncbi request reprint Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Medizinische Facultät der Humboldt Universität zu Berlin, Germany
    Anticancer Drugs 13:833-8. 2002
  8. ncbi request reprint Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 10:699-704. 1999
  9. ncbi request reprint The role of gemcitabine alone and in combination in the treatment of pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 11:771-86. 2000
  10. ncbi request reprint Adjuvant therapy in pancreatic cancer: a critical appraisal
    Helmut Oettle
    Department of Medical Hematology and Oncology, Charité Berlin University School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    Drugs 67:2293-310. 2007

Detail Information

Publications42

  1. doi request reprint Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial
    Helmut Oettle
    Medizinische Klinik mit Schwerpunkt Hamatologie, Onkologie und Tumorimmunologie, Charite Universitatsmedizin Berlin, Berlin, Germany
    JAMA 310:1473-81. 2013
    ..Gemcitabine-based chemotherapy is standard treatment for advanced pancreatic cancer, but its effect on survival in the adjuvant setting has not been demonstrated...
  2. pmc Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno Riess
    Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
    BMC Cancer 8:361. 2008
    ..This phase IIb study was designed to analyze the efficacy of enoxaparin in patients with locally advanced or metastatic pancreatic cancer undergoing systemic chemotherapy...
  3. pmc A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Helmut Friess
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    BMC Cancer 6:285. 2006
    ..In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer...
  4. pmc Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO Study Group, Augustenburger Platz 1, Berlin, Germany
    BMC Cancer 10:86. 2010
    ..The positive influence of BIA determinate predictors by additional nutrition is currently under discussion...
  5. ncbi request reprint Recombinant human erythropoietin in the treatment of head and neck tumour anaemia
    H Oettle
    Charite Campus Virchow Klinikum, Medical Faculty of the Humboldt University in Berlin Germany
    Int J Oral Maxillofac Surg 30:148-55. 2001
    ..Recombinant human erythropoietin administration improves the therapeutic outcome and the patients' prognosis...
  6. ncbi request reprint Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial
    Helmut Oettle
    Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    JAMA 297:267-77. 2007
    ..The role of adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recommended standard exists...
  7. ncbi request reprint Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Medizinische Facultät der Humboldt Universität zu Berlin, Germany
    Anticancer Drugs 13:833-8. 2002
    ....
  8. ncbi request reprint Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 10:699-704. 1999
    ..The median time to progressive disease was 31 weeks (range 5-50 weeks). A phase 11 trial is underway to further assess the activity of this combination at the recommended dose of 750 mg/m2 5-FU...
  9. ncbi request reprint The role of gemcitabine alone and in combination in the treatment of pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 11:771-86. 2000
    ..The data suggest that gemcitabine in combination with biomodulated 5-FU should be considered the standard palliative treatment to which other new drug combinations or combined modality chemoradiation regimens should be compared...
  10. ncbi request reprint Adjuvant therapy in pancreatic cancer: a critical appraisal
    Helmut Oettle
    Department of Medical Hematology and Oncology, Charité Berlin University School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    Drugs 67:2293-310. 2007
    ....
  11. pmc Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report
    S Serke
    Department of Haematology Oncology, Charite, Campus Virchow Klinikum, , Berlin, Germany
    Br J Cancer 79:1519-21. 1999
    ..Re-exposure to gemcitabine 6 months after the episode of HUS instituted for progressive carcinoma, thus far has not caused another episode of HUS...
  12. ncbi request reprint Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
    H Oettle
    Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Berlin, Germany
    Anticancer Drugs 11:635-8. 2000
    ..This opens up an additional therapeutic option for a selected patient group with a poor prognosis so far...
  13. ncbi request reprint A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    H Oettle
    University of Berlin, Berlin, Germany
    Ann Oncol 16:1639-45. 2005
    ..This randomized phase III study compared the overall survival (OS) of pemetrexed plus gemcitabine (PG) versus standard gemcitabine (G) in patients with advanced pancreatic cancer...
  14. ncbi request reprint Gemcitabine in the treatment of advanced head and neck cancer
    J D Raguse
    Clinic and Policlinic for Oral and Maxillofacial Surgery, Plastic Surgery, Germany
    Clin Oncol (R Coll Radiol) 17:425-9. 2005
    ..Gemcitabine has demonstrated a broad spectrum anti-tumoural effect and a favourable toxicity profile. These attributes prompted us to introduce gemcitabine into the treatment of head-and-neck tumours...
  15. ncbi request reprint [Adjuvant therapy of pancreatic carcinoma]
    H Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin
    Praxis (Bern 1994) 89:2017-25. 2000
    ..In a multicenter German trial the benefit of gemcitabene as weekly monotherapy for 6 months is investigated. The treatment starts soon after resection due to low toxicity and good patient compliance...
  16. ncbi request reprint Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossa
    J D Raguse
    Klinik und Poliklinik fur Mund, Kiefer und Gesichtschirurgie, Plastische Operationen, Germany
    Int J Oral Maxillofac Surg 33:606-9. 2004
    ..The patient received interferon alpha2a subcutaneously for 6 months. A slow but steady reduction of the tumour was observed, and pre-existing symptoms disappeared...
  17. ncbi request reprint [Current concepts and recent developments of laser ablation in tumor therapy]
    C Stroszczynski
    Klinik für Strahlenheilkunde der Charité, Campus Virchow Klinikum und Campus Buch Medizinische Fakultät der Humboldt Universität zu Berlin
    Radiologe 44:320-9. 2004
    ..The procedure was done using a combination of imaging modalities (CT/MRI, CT/US) or only closed high field MRI (1.5 T). All patients received an MRI-scan immediately after laser ablation...
  18. ncbi request reprint [Potential advantages of the MRI for the radiofrequency ablation of liver tumors]
    G Gaffke
    Klinik für Strahlenheilkunde und Poliklinik, Charite, Universitatsmedizin Berlin
    Rofo 177:77-83. 2005
    ..To present first results of radiofrequency ablation of liver tumors using a new MR compatible applicator...
  19. ncbi request reprint A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Ann Oncol 11:1267-72. 2000
    ..The present study was initiated to investigate the efficacy of gemcitabine in combination with 5-FU-FA...
  20. ncbi request reprint [Adjuvant treatment of pancreatic cancer]
    H Oettle
    Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie
    Zentralbl Chir 128:411-8. 2003
    ..These studies have also included arms with gemcitabine, the current standard for palliative treatment of pancreatic cancer, and will hopefully allow firm conclusions as to the role of postoperative chemotherapy...
  21. doi request reprint Adjuvant therapy of pancreatic cancer
    Andreas Hilbig
    Campus Virchow Klinikum, Medizinische Klinik M S Hämatologie und Onkologie Augustenburger Platz 1, 13353 Berlin, Germany
    Expert Rev Anticancer Ther 10:485-91. 2010
    ..Early data from the European Study Group for Pancreatic Cancer-3(v2) trial revealed no difference in terms of overall survival between 5-fluorouracil/folinic acid and gemcitabine after resection of pancreatic cancer...
  22. ncbi request reprint Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9
    Jan Däbritz
    Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Humboldt University of Berlin, Berlin, Germany
    Pancreas 38:534-41. 2009
    ..We followed up the presence of Kirsten rat sarcoma (K-ras) mutations in plasma DNA and assessed its clinical value in patients with pancreatic cancer...
  23. ncbi request reprint Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour
    Jan Dirk Raguse
    Klinik fur Mund, Kiefer und Gesichtschirurgie, klinische Navigation und Robotik Plastische Operationen, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburgerplatz 1, 13353 Berlin, Germany
    Oral Oncol 40:228-30. 2004
    ..case demonstrates the clinical efficacy of the antiangiogenetic agent cilengitide, in combination with gemcitabine, in inhibiting rapid growth of highly vascularized tumour and highlights the potential of this new therapeutic agent..
  24. doi request reprint Gemcitabine in the treatment of metastatic pancreatic cancer
    Andreas Hilbig
    Department of Medical Hematology and Oncology, Charite School of Medicine, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Expert Rev Anticancer Ther 8:511-23. 2008
    ..The emerging role of combinations of gemcitabine with novel targeted agents, including small-molecule inhibitors and other investigational drugs, is also discussed...
  25. doi request reprint Second-line therapy in refractory pancreatic cancer. results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, CharitéCentrum fur Tumormedizin, Medizinische Klinik m S Hamatologie Onkologie, Berlin, Germany
    Onkologie 32:99-102. 2009
    ....
  26. ncbi request reprint Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study
    Jan Dirk Raguse
    Clinic and Policlinic for Oral and Maxillofacial Surgery, Plastic Surgery, Clinical Navigation and Robotics, Charite Universitatsmedizin Berlin, Campus Virchow Hospital, Augustenburger Platz 1, 13353 Berlin, Germany
    Oral Oncol 42:614-8. 2006
    ..In this small phase II study the combination of oxaliplatin, FA and 5-FU (OFF) demonstrated relative to the standard regimen of cisplatin and 5-FU a high antitumoural activity in previously treated scchn with favourable toxicity profile...
  27. ncbi request reprint Quantitation of cytomegalovirus (hCMV) DNA and beta-actin DNA by duplex real-time fluorescence PCR in solid organ (liver) transplant recipients
    Joachim Hänfler
    Department of Medicine, Division of Hematology and Oncology, Charite Campus Virchow Klinikum, Humboldt University Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
    Med Microbiol Immunol 192:197-204. 2003
    ..We conclude that with the presented method the reliability of hCMV quantitation via real-time PCR can be substantially increased and may be used to monitor hCMV kinetics in vivo...
  28. ncbi request reprint Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
    Helmut Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Berlin, Germany
    Cancer 95:912-22. 2002
    ..However, the results of ongoing Phase III studies must be reviewed before a definitive statement can be made regarding the value of this combination in the treatment of pancreatic cancer...
  29. ncbi request reprint Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis
    Daniel Seehofer
    Department of General, Visceral and Transplant Surgery, Humboldt University of Berlin, Berlin, Germany
    Transpl Int 18:941-8. 2005
    ..As D+R- patients still more often develop symptomatic disease, pre-emptive therapy could be useful in this patient group...
  30. ncbi request reprint Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI
    Juri Ruf
    Klinik fur Strahlenheilkunde und PET Zentrum Berlin, Berlin, Germany
    Pancreatology 5:266-72. 2005
    ..To determine the value of fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the detection of recurrent pancreatic cancer in comparison to computed tomography (CT) and magnetic resonance imaging (MRI)...
  31. ncbi request reprint [Up-to-date diagnosis and treatment of advanced pancreatic cancer]
    J M Stieler
    Medizinische Klinik mit Schwerpunkt Hämatologie Onkologie, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin
    Dtsch Med Wochenschr 130:2146-8. 2005
    ..Treatment of pain, malabsorption and maldigestion is an important issue of supportive therapy in pancreatic cancer patients...
  32. ncbi request reprint Histopathological correlation to MRI findings during and after laser-induced thermotherapy in a pig pancreas model
    C Stroszczynski
    Radiology Charité Campus Buch, Robert Roessle Klinik am Max Delbrueck Center of Molecular Medicine, Berlin, Germany
    Invest Radiol 36:413-21. 2001
    ..To investigate whether percutaneous laser-induced thermotherapy (LITT) with continuous magnetic resonance (MR) monitoring of thermal effects within the pancreas is feasible in a porcine model...
  33. ncbi request reprint Pancreatic cancer: step by step forward
    H Riess
    Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Berlin, Germany
    Recent Results Cancer Res 177:1-2. 2008
  34. ncbi request reprint Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia
    Roman Preston
    Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    Leuk Res 34:883-91. 2010
    ..Correlation with clinical data suggests K-ras mutations to be associated with higher age and a better response to anti-leukemic chemotherapy...
  35. ncbi request reprint Role of F18-FDG PET for monitoring of radiochemotherapy -- estimation of detectable number of tumour cells
    J Ruf
    Klinik fur Strahlenheilkunde, Charite, Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Onkologie 27:287-90. 2004
    ..FDG-PET has been proven to be useful for the diagnosis of pancreatic cancer. However, no quantitative data exist concerning its sensitivity for treatment monitoring or early diagnosis...
  36. pmc Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes
    J Däbritz
    Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Augustenburger Platz 1, 13353 Berlin, Germany
    Br J Cancer 92:405-12. 2005
    ..In addition, this method can be adapted for simultanous detection of multiple mutations and quantitation...
  37. ncbi request reprint Use of semiflexible applicators for radiofrequency ablation of liver tumors
    G Gaffke
    Klinik für Strahlenheilkunde und Poliklinik, Charite, Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
    Cardiovasc Intervent Radiol 29:270-5. 2006
    ..To evaluate the feasibility and potential advantages of the radiofrequency ablation of liver tumors using new MRI-compatible semiflexible applicators in a closed-bore high-field MRI scanner...
  38. ncbi request reprint Presence of human beta- and gamma-herpes virus DNA in Hodgkin's disease
    C A Schmidt
    Abteilung fur Innere Medizin, Hämatologie und Onkologie, Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Leuk Res 24:865-70. 2000
    ..In contrast to EBV, beta-herpes viruses are therefore unlikely to have a role in the aetiology of HD. Rather, the presence of these viruses seems to reflect impaired immunological surveillance...
  39. doi request reprint The role of epoxide hydrolase Y113H gene variant in pancreatic diseases
    Johann Ockenga
    Department of Gastroenterology, Hepatology and Endocrinology, Charite, Campus Mitte, Germany
    Pancreas 38:e97-e101. 2009
    ..We studied the role of the EPHX1 c.337T>C (p.Y113H) variant, whichleads to altered enzyme activity, in pancreatic diseases...
  40. ncbi request reprint Quantitation of the spliced late gene of human cytomegalovirus and its kinetics during experimental infection
    Joachim Hänfler
    Department of Medicine, Humboldt University Berlin, Germany
    Med Microbiol Immunol 190:161-5. 2002
    ....
  41. ncbi request reprint Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule
    Lars Meyer
    J Clin Oncol 20:1146-7. 2002
  42. ncbi request reprint Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Hermann Einsele
    Dept of Hematology, Oncology, Medical Clinic II, University of Tubingen, Otfried Muller Strasse 10, 72076, Tubingen, Germany
    Ann Hematol 82:S175-85. 2003
    ..Infection-associated mortality, for example, is significantly higher following engraftment than during the short neutropenic period that immediately follows transplantation...